Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $183
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice TargetHot
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $163 to $183.